Literature DB >> 29224406

Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens.

Alexander M Sherwood1, Thomas E Prisinzano1.   

Abstract

Entities:  

Keywords:  Anxiety; MDMA; PTSD; depression; drug policy; entactogen; hallucinogen; ketamine; psilocybin; psychedelic

Mesh：

Substances：

Year:  2017        PMID： 29224406      PMCID： PMC6121772          DOI： 10.1080/17512433.2018.1415755

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN： 1751-2433            Impact factor:   5.045


× No keyword cloud information.
  15 in total

Review 1.  Estimating the true global burden of mental illness.

Authors:  Daniel Vigo; Graham Thornicroft; Rifat Atun
Journal:  Lancet Psychiatry       Date:  2016-02       Impact factor: 27.083

Review 2.  Psychedelics as Medicines: An Emerging New Paradigm.

Authors:  D E Nichols; M W Johnson; C D Nichols
Journal:  Clin Pharmacol Ther       Date:  2016-12-26       Impact factor: 6.875

3.  Effects of a ketamine metabolite on synaptic NMDAR function.

Authors:  Kanzo Suzuki; Elena Nosyreva; Kevin W Hunt; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2017-06-21       Impact factor: 49.962

4.  Retuning brain circuitry to treat mental illness: The role of functional neuroimaging. Commentary for the special issue: Mechanisms of change.

Authors:  Alain Dagher
Journal:  Neuroimage       Date:  2017-01-12       Impact factor: 6.556

5.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 7.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.

Authors:  Robin L Carhart-Harris; Leor Roseman; Mark Bolstridge; Lysia Demetriou; J Nienke Pannekoek; Matthew B Wall; Mark Tanner; Mendel Kaelen; John McGonigle; Kevin Murphy; Robert Leech; H Valerie Curran; David J Nutt
Journal:  Sci Rep       Date:  2017-10-13       Impact factor: 4.379

9.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

Review 10.  Modern Clinical Research on LSD.

Authors:  Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2017-04-27       Impact factor: 7.853
View more
  8 in total

1.  Rapid well-plate assays for motor and social behaviors in larval zebrafish.

Authors:  Qiaosen Shen; Lisa Truong; Michael T Simonich; Changjiang Huang; Robyn L Tanguay; Qiaoxiang Dong
Journal:  Behav Brain Res       Date:  2020-05-16       Impact factor: 3.332

2.  Opportunities in Novel Psychotropic Drug Design from Natural Compounds.

Authors:  Siu Wa Tang; Wayne H Tang
Journal:  Int J Neuropsychopharmacol       Date:  2019-09-01       Impact factor: 5.176

3.  Simultaneous Production of Psilocybin and a Cocktail of β-Carboline Monoamine Oxidase Inhibitors in "Magic" Mushrooms.

Authors:  Felix Blei; Sebastian Dörner; Janis Fricke; Florian Baldeweg; Felix Trottmann; Anna Komor; Florian Meyer; Christian Hertweck; Dirk Hoffmeister
Journal:  Chemistry       Date:  2019-12-13       Impact factor: 5.236

4.  Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use.

Authors:  Alexander M Sherwood; Romain Claveau; Rafael Lancelotta; Kristi W Kaylo; Kelsey Lenoch
Journal:  ACS Omega       Date:  2020-12-02

5.  Psilocybin: crystal structure solutions enable phase analysis of prior art and recently patented examples.

Authors:  Alexander M Sherwood; Robert B Kargbo; Kristi W Kaylo; Nicholas V Cozzi; Poncho Meisenheimer; James A Kaduk
Journal:  Acta Crystallogr C Struct Chem       Date:  2022-01-01       Impact factor: 1.172

Review 6.  Self-Enhancement and the Medial Prefrontal Cortex: The Convergence of Clinical and Experimental Findings.

Authors:  Saeed Yasin; Anjel Fierst; Harper Keenan; Amelia Knapp; Katrina Gallione; Tessa Westlund; Sydney Kirschner; Sahana Vaidya; Christina Qiu; Audrey Rougebec; Elodie Morss; Jack Lebiedzinski; Maya Dejean; Julian Paul Keenan
Journal:  Brain Sci       Date:  2022-08-19

7.  Crystallographic hallucinations.

Authors:  Brian H Toby
Journal:  Acta Crystallogr C Struct Chem       Date:  2022-01-27       Impact factor: 1.172

Review 8.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.